Previous Article | Next Article ![]()
Infection and Immunity, October 2007, p. 4838-4850, Vol. 75, No. 10
0019-9567/07/$08.00+0 doi:10.1128/IAI.00635-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.
,
Andrew V. Oleinikov,1
Eddie Rossnagle,1
Jason P. Wendler,1,
Theonest K. Mutabingwa,1,2,3
Michal Fried,1,4 and
Patrick E. Duffy1,4*
Seattle Biomedical Research Institute, Seattle, Washington 98109,1 National Institute for Medical Research, Dar es Salaam, Tanzania,2 Muheza Designated District Hospital, Muheza, Tanzania,3 University of Washington, Seattle, Washington 981954
Received 4 May 2007/ Returned for modification 17 June 2007/ Accepted 1 August 2007
|
|
|---|
|
|
|---|
Placental parasites have distinct properties that suggest a unique repertoire of surface antigens. Infected erythrocytes (IE) in the placenta adhere to low-sulfated forms of chondroitin sulfate A (CSA), a glycosaminoglycan found on the surface of the syncytiotrophoblast (1, 2, 20, 22, 25) and throughout the intervillous spaces of infected placentas (47). Although the distribution of CSA on vascular surfaces has not been fully defined, CSA binding appears to be largely associated with parasites from pregnant women (18, 57). Conversely, placental parasites do not typically bind CD36, ICAM-1, or other endothelial receptors (17, 57) that commonly support binding of parasites associated with other malaria syndromes (5, 6, 28, 64).
The frequency and severity of placental malaria decrease over successive pregnancies, as women acquire adhesion-blocking antibodies against placental IE (21). Serum immunoglobulin G (IgG) from multigravid women living in areas of endemicity has been shown to block adhesion of placental or CSA-selected parasites collected from different continents (18, 21, 54, 66). Adhesion-blocking antibodies are not detected in males or women before first pregnancy. This pattern of naturally acquired immunity is consistent with repeated exposure to a finite number of antigens during pregnancy that are not seen in childhood infections, raising expectations that a vaccine can be developed once the IE surface antigens of placental parasites are identified.
The search for IE surface antigens of placental parasites has focused on the var gene family. var genes encode antigenically varied 200- to 400-kDa multidomain IE surface proteins called PfEMP1 that have been implicated in adhesion to other receptors (62, 65). There are 59 var genes in the 3D7 P. falciparum genome (24) and probably similar numbers in other strains (33).
var gene variants varCS2 (53) and FCR3.varCSA (var1csa) (10) have both been linked to CSA binding in studies of parasites selected in vitro. Deletion of FCR3.varCSA resulted in initial loss of CSA binding, suggesting a role for VAR1CSA in binding of the FCR3 parasite line to CSA. However, other studies suggest that var1csa is not central to adhesion of placental parasites. Transcription of var1csa is not restricted to placental parasites (19), and seroreactivity to expressed VAR1CSA is not parity related (31, 50). After selection on CSA, the FCR3 knockout parasite regained binding to CSA and expressed a novel PfEMP1 gene, subsequently shown to be var2csa (3, 23).
A comprehensive analysis of var gene transcription in CSA-selected NF54 laboratory parasites revealed that PFL0030c, now known as var2csa, was transcribed at high levels (60). Transcription of var2csa has been confirmed in other CSA-selected laboratory strains as well as isolates from pregnant women (13, 15). var2csa was recently shown to be the most highly expressed var gene detected in placental parasites from Malawi, although one placental parasite sample preferentially expressed the DBL2
domain of varCS2 (14). CSA-selected parasites expressing var2csa are recognized by sera from Ghana and Senegal in a parity- and gender-specific manner (60, 67) that correlates with protection.
The mass of data accumulated over the last few years is consistent with the hypothesis that VAR2CSA is the dominant PfEMP1 associated with parasite adhesion to the placenta. However, fundamental gaps remain in our understanding of placental parasites. While VAR2CSA has been shown to be localized to the IE cell surfaces of CSA-selected parasites (4, 15), there are no published reports of VAR2CSA cell surface localization in parasites from pregnant women. Cross-linking experiments examining binding of IE surface proteins to CSA showed that an unidentified 22-kDa protein and not VAR2CSA bound to CSA (26), and no studies have demonstrated that soluble VAR2CSA can inhibit binding of placental parasites. These findings raise the possibility that other proteins in addition to VAR2CSA are required for the placental parasite phenotype, for example, as part of a multimeric protein complex at the IE surface (26), which could also reconcile the biochemical properties of PfEMP1 with its membrane topology (51). PfEMP1 is synthesized as a peripheral membrane protein (51) and appears to be part of a complex, rather than in vesicles in the IE cytosol (32), prior to localization to the Maurer's cleft and subsequent insertion in the erythrocyte membrane (35, 43, 51).
Since the erythrocyte lacks a protein transport apparatus, many of the necessary components must be exported by the parasite. The predicted secretome responsible for erythrocyte remodeling, protein transport, and adhesion properties is composed of about 400 proteins with sorting motifs that direct proteins beyond the parasitophorous vacuole membrane plus additional proteins that lack these motifs (7, 12, 29, 30, 44, 48, 63). Many secretome proteins are encoded by members of paralogous families with unknown functions that show dramatic expansion in P. falciparum and may define specific virulence properties.
In an effort to characterize the placenta binding phenotype of clinical parasites and to identify novel antigens that are expressed by parasites causing infections, we examined the whole-genome transcriptional profiles of parasites collected from Tanzanian women with pregnancy malaria. Parasites were profiled either directly after collection in the clinic or after a maximum of 20 h in culture so that gene expression patterns characteristic of parasites causing disease would be maintained. Both circulating early-stage parasites and sequestered late-stage parasites from women with pregnancy malaria were analyzed so that the transcriptional profiles of parasites just prior to and during sequestration could be determined. We found that increased var2csa expression is always observed in maternal parasites at both stages of intraerythrocytic development and that a suite of five additional genes, all with unknown functions, is also consistently up-regulated by these parasites.
|
|
|---|
Placental parasites were obtained as previously described (17). Parasites from the peripheral circulation of mothers and children were cultured and tested for adhesion to immobilized purified receptors, including CSA, hyaluronic acid (HA), thrombospondin (TSP), ICAM-1, CD36, and bovine serum albumin (BSA) (control). Assays were performed within 24 h of sample collection (16).
RNA preparation and microarray hybridization. Intervillous blood was obtained by mechanical grinding of placentas, and intraerythrocytic parasites were released from red blood cells by saponin lysis. The released parasites were stored in RNA Later solution (Ambion) at –20°C and subsequently solubilized in TRIzol (Invitrogen). Peripheral parasites from mothers and children were collected and stored in either TRIzol or RNA Wiz (Ambion) and stored at –80°C. Peripheral parasites from children were cultured for 20 h until parasites matured to the trophozoite stage, solubilized in TRIzol, and stored at –80°C.
RNA was isolated according to the manufacturer's instructions. Microarray probes were prepared using a MessageAmpII aminoallyl labeling kit, starting with 1 to 3 µg of total RNA from each sample, following the kit instructions (Ambion). Probes were coupled to Cy3 and Cy5 monoesters (GE Healthcare Biosciences). Probe samples to be compared were combined and fragmented with RNA fragmentation reagent (Ambion).
All slides were prehybridized at 63°C with 3x SSC (1x SSC is 0.15 M NaCl plus 0.015 M sodium citrate), 0.1% sodium dodecyl sulfate (SDS), 0.1 mg/ml BSA for 60 min to 4 h and then washed in nuclease-free water and dried. The hybridization buffer was 3x SSC, 25 mM HEPES (pH 7.5), 0.75 mg/ml poly(A) DNA (Sigma), 0.2% SDS. Differential gene expression was determined by direct comparison of 5 µg of a labeled probe from maternal-parasite RNA to 5 µg of a labeled probe with comparable specific activity from child-derived-parasite RNA. Multiple comparisons were made for each clinical parasite sample. Slides were hybridized at 63°C for 16 to 20 h and washed in 2x SSC, 0.2% SDS, followed by a wash in 0.1x SSC.
Data were acquired with GenePix Pro 4000A (Molecular Devices) and analyzed using GenePix 5.1 (Axon Instruments) and Acuity 4.0 (Molecular Devices) software. Data were normalized using a locally weighted linear regression algorithm without background subtraction. Unflagged spots whose background-subtracted intensities were 3 standard deviations above the local background level were analyzed.
Microarray fabrication. Microarrays were prepared by spotting the P. falciparum genome set of 70-mer oligonucleotides (Operon Biotechnologies) and 396 PfEMP1 70-mer oligonucleotides. These include the primary 3D7 elements from the Operon set, additional domain-specific elements designed for selected 3D7 var genes, elements from sequences obtained from field studies, the conserved regions from type A PfEMP1 genes implicated in severe malaria (37), and consensus var2csa elements designed by aligning 3D7, IT4, and DD2 strains of P. falciparum. In total, 4,872 3D7 P. falciparum genes were represented by oligonucleotide probes. Custom oligonucleotides were designed manually or using OligoArraySelector software and then synthesized (Illumina). All oligonucleotides were resuspended in 3x SSC to a concentration of 50 µM and spotted in duplicate on each UltraGapII slide (Corning), using a Gene Machine GR-04 Omnigrid oligonucleotide arrayer (Gene Machines). Slides were cross-linked and blocked using protocols from http://derisilab.ucsf.edu.
Quantitative reverse transcription-PCR (Q-PCR).
DNA was removed from RNA with Turbo DNase (Ambion), following the kit instructions. RNA was reverse transcribed for 2 h at 46°C using Superscript III (Invitrogen) and primed with random nonamers (Sigma Aldrich). RNA from ring stage parasites was prepared by amplification using a Message Amp II kit (Ambion). PCR primers for selected genes were designed using Primer3 software (58). Real-time PCR was performed with the 7500 fast real-time PCR system (Applied Biosystems) for 45 cycles at 59oC using a SYBR green master mix kit (Applied Biosystems) and 0.5 mM primers. PCRs were performed in triplicate. Relative quantitation of RNA expression was done using the 
CT method (user bulletin 2; Applied Biosystems), using seryl-tRNA synthetase and fructose biphosphate aldolase as constitutive controls (60). Maternal samples were compared to samples from children, which served as the calibrator. P values were determined using the Kruskal-Wallis algorithm. Primer pairs used in this study are listed in Table 1.
|
View this table: [in a new window] |
TABLE 1. Real-time-PCR primers
|
Multiple regression analysis. For each probe, the log2 intensities of all samples were calculated from microarray ratios by using multiple regression analysis. The design matrix was designated with values 1 and –1 in positions where samples were arrays in Cy5 and Cy3, respectively. P values corrected for multiple testing were calculated according to the Westfall-Young algorithm (69).
Hierarchical clustering of timing profiles. Timing profiles in correlation distances from different microarray slides from the same clinical samples were calculated, and their means were used for cluster analysis. Hierarchical clustering was performed using Euclidean distances and an average linkage algorithm.
PCA of the blood stage cycle. The 51 HB3 blood stage microarrays with valid spots (see above), plus all clinical microarrays from the current study, were normalized by total intensity and log transformed. If valid signals for a particular element existed in at least half of the arrays for a clinical sample, their mean value was used as the intensity of the element. Between 51 blood stage arrays and 20 clinical samples, there was a data set of 1,554 shared elements. Principal-component analysis (PCA) of the 51 blood stage time points (restricted to the described 1,554-element data set) showed that the first three components can be retained, and they explain 93% of the variance. After varimax rotation, these three principal components corresponded to the late ring-early trophozoite, late trophozoite-early schizont, and late schizont-early ring stages (see Fig. S3 in the supplemental material). Loading of clinical samples on the principal components was calculated as a correlation coefficient between each clinical sample and the principal components.
PfEMP1 gene expression analysis. All microarray elements were blasted against 97 PfEMP1 genes, pseudogenes, and truncated genes from the 3D7 strain. Partial homology with an E score of 6e–10 or less was considered a hit (see Table S3 in the supplemental material). Three hundred ninety-six elements were selected. The intensity of each element in each array was divided by the total intensity for the corresponding array. If the intensities of duplicate spots differed twofold or more, both spots were considered invalid. Otherwise, their average value was taken. If any array had an element whose intensity differed more than threefold from the mean intensity of the element for that clinical sample across all applicable arrays, then that element was excluded from further analysis. After this step, 377 elements had consistent measurements across all clinical samples. The switched-off expression level of a particular element was calculated as the mean expression level of the three lowest-expressing clinical samples (out of 11) of the same element. As a compromise between sensitivity in detection of switched-on expression and reduction of false scoring due to low-homology cross-hybridization by other PfEMP1 genes, we counted an element as switched on in a clinical sample only if its mean expression level exceeded its switched-off expression level eightfold or more.
Cloning and expression of PFD1140w. cDNA encoding the predicted extracellular portion of PFD1140w (amino acid residues 34 through 347) was amplified using genomic 3D7 DNA and PCR with two primers: forward (CCCCTCGAGATGGACTACAAAGACGATGACGATAAGAAAAGTTCTAGTGGCTCATGTGTTAATAG) and reverse (CCCGGATCCTTAATTAGACAAAGCATCAATAATTTTTTTTTC). The forward primer introduced the coding sequence for the FLAG epitope. The PCR fragment was cloned into the XhoI and BamHI restriction sites of the pEU-E01-MCS vector (CellFree Sciences). Transcription and translation in the wheat germ cell-free system were performed according to the manufacturer's instructions. To confirm synthesis, synthetic protein was purified on anti-FLAG resin (Sigma) by using 3x FLAG peptide and analyzed by SDS gel electrophoresis and Coomassie blue staining (see Fig. 5A).
![]() View larger version (50K): [in a new window] |
FIG. 5. Coordinated expression of genes with increased expression in parasites from pregnant women. (A to F) In microarray data from reference 8, K means clustering was used to define six major expression profiles of genes during intraerythrocytic development of laboratory parasites. Four genes that are up-regulated in parasites from pregnant women (PFB0115w, PFD1140w, PFI1785w, and PFL0050c) (highlighted in red) cluster with a single group of genes that are most highly expressed during late-ring/early-trophozoite development.
|
|
|
|---|
|
View this table: [in a new window] |
TABLE 2. Binding phenotypes of parasites from women with pregnancy malaria and from children with malaria
|
|
View this table: [in a new window] |
TABLE 3. Summary of cell cycle positions of microarray samples as determined by Euclidean distance and correlation distance comparison with the 48-h asexual stage transcriptome of P. falciparum
|
![]() View larger version (32K): [in a new window] |
FIG. 1. Timing analysis of each clinical sample in the 48-h intraerythrocytic cycle. (A) Correlation distance plots comparing averages for replicates for each peripheral blood parasite sample with the 51 time points from the 48-h HB3 transcriptional profile analysis (8). The three peripheral samples from women with pregnancy malaria are shown in green, and eight peripheral samples from children with malaria are shown in black. (B) Correlation distance plot comparing averages for replicate samples of placental parasite PLCNT 166 and averages for replicates of CH TR 852. (C and D) Euclidean distance plots for samples in panels A and B, respectively. (E). Hierarchical clustering of correlation time profiles of all clinical samples. (F). Placental trophozoite samples and cultured trophozoite samples from children were loaded onto three principal-component coordinates to compare their positions in the cell cycle. Child-derived trophozoite samples CH-TR 095, CH-TR 852, and CH-TR 669 and placental samples PLCNT 038, PLCNT 222, and PLCNT 918 are comparably positioned (shown in blue). Placental samples PLCNT166 and PLCNT 661 have greater representation in the late ring-early trophozoite component (shown in red). Sample CH-TR 662 (in red) has a distinct timing profile. The 31-h cluster is shown in blue. Samples are identified left to right.
|
var2csa is highly expressed by peripheral parasites from pregnant women.
We aligned 3D7, IT4, and Dd2 sequences of var2csa and identified nine unique, well conserved 70-mer sequences for use as microarray elements (Fig. 2). These elements are also generally conserved in the recently sequenced Ghanaian clinical parasite sample (Fig. 2). Multiple pairwise comparisons between three maternal peripheral samples and eight samples from children were performed (see Table S1 in the supplemental material). Four out of seven var2csa elements were well detected by a probe prepared from maternal parasites; two of three elements that performed poorly were the least conserved compared to the Ghanaian sequence. Two additional elements with greater than 90% sequence identity with var2csa were discovered during analysis of the hybridization experiments. Element var2csa 4038 (derived from a cDNA clone of the placental parasite pl28b) was originally thought to be a divergent DBL
domain of var1csa (19) but is identified here as a clinical variant of var2csa. The other element maps to the probable 5' untranslated region (37) of var2csa 653 bp upstream from the putative initiator methionine (Fig. 2).
|
View larger version (11K): [in a new window] |
FIG. 2. var2csa microarray elements. Schematic of consensus 70-mer nucleotide microarray elements showing DBL domain assignments. Elements were designed by aligning var2csa sequences from different laboratory strains of P. falciparum. 3D7, Ghana-1, and Ghana-2 indicate percent sequence identity of array elements with 3D7 and two recently sequenced var2csa homologs obtained from a clinical sample (Ghanaian P. falciparum genome sequence; Sanger Center). Operon element M59463_1 (made against MAL13P1.353, no longer annotated) maps to bp –653 relative to the PFL0030c translation start site. The element at position 4038 was designed from a DNA sequence amplified from placental isolate pl 28b, using degenerate DBL domain primers (19). Element positions are relative to the 3D7 gene PFL0030c. UTR, untranslated region.
|
![]() View larger version (58K): [in a new window] |
FIG. 3. PfEMP1 gene expression. (A) Checkerboard representation of expression by members of the PfEMP1 gene family by different clinical samples. Gray boxes denote samples that hybridized to that PfEMP1 probe. PfEMP1 genes were grouped according to the classification scheme in reference 37. The probe position for each PfEMP1 element is based on the 3D7 nucleotide sequence and is indicated as part of each gene name. (B, C, D) Comparison of signal intensities (filled bars) among clinical samples for elements PFL0030c-5053 (B), PFC0005w-4450 (C), and PFL1955w-5979 (D). Open bars show background intensity.
|
![]() View larger version (47K): [in a new window] |
FIG. 4. Genes with increased expression in parasites obtained from women with pregnancy malaria. (A) Heat map of highly up-regulated genes expressed by peripheral parasites from women with pregnancy malaria based on Euclidean hierarchical clustering. (B) Expression levels of up-regulated genes identified by microarray analysis compared to seryl tRNA synthase constitutive control levels as detected by Q-PCR. (C) Heat map of transcription by trophozoite stage parasites, focused on the var2csa gene cluster identified in maternal peripheral parasites. (D) Q-PCR analysis of trophozoite stage gene expression.
|
In total, 8 different maternal samples derived from either peripheral blood samples or placentas from women with pregnancy malaria were compared with 11 parasite samples collected from peripheral blood samples from children and assayed directly or cultured to the trophozoite stage. A small number of genes were found to be expressed at higher levels by parasites from women with pregnancy malaria. Despite differences in the developmental stages of maternal parasites, six genes were common to both analyses. In addition to these six genes, MAL7P1.225 and PF10_0013 were more highly expressed by placental parasites, while MAL13P1.470 was more highly expressed by ring stage parasites from pregnant women.
Genes up-regulated in pregnancy malaria parasites have coordinated timing of expression. The transcription profiles for genes that differ most consistently over the course of blood stage development were extracted from the intraerythrocytic cycle database (malaria transcriptome database [http://malaria.ucsf.edu]). K means clustering produced six expression profiles (Fig. 5). Four of six clusters have well-defined expression patterns roughly corresponding to peaks at the ring stage, late ring/early trophozoite stage, mid- to late trophozoite stage, and schizont/early ring stage (Fig. 5A, B, C, and D). One cluster is less well defined and has broader transcript timing (Fig. 5E), and one cluster is composed of genes whose expression levels are close to the background level across the intraerythrocytic cycle (Fig. 5F).
The genes (PFB0115w, PFD1140w, PFI1785w, and PFL0050c) that were most highly expressed in both peripheral and placental parasites from pregnant women cluster with genes expressed maximally at the late ring/early trophozoite stage (Fig. 5A). This expression pattern coincides with the disappearance of trophozoite stage parasites from the peripheral circulation because of sequestration in tissues. Expression of var2csa was not detected in the HB3 time series; maximal var2csa expression was observed at 6 hours postinfection in the 3D7 blood stage time course (malaria transcriptome database [http://malaria.ucsf.edu]). Other studies indicate that the var2csa message is present during the ring and early trophozoite stages (60). MAL13P1.320 does not follow the same transcription profile and instead clusters with genes expressed at a low level across much of the HB3 cell cycle (Fig. 5F).
Serum recognition by PFD1140w is gender and parity specific. Genes with increased transcription in parasites from pregnant women were expressed by in vitro translation and tested by an enzyme-linked immunosorbent assay for reactivity against East African sera. Thirty-three sera from multigravid and 20 sera from primigravid women from a high-malaria-transmission area in Tanzania were compared for reactivity against PFD1140w, PFI1785w, PFB0115w, MAL13P1.320, and MAL13P1.470. Reactivity against recombinant PFD1140w was significantly higher with sera from multigravid women, suggesting that antibodies are acquired over successive pregnancies (Fig. 6). None of the other expressed proteins showed significant parity-specific seroreactivity profiles. PFB0115w was more reactive against sera from multigravid women, but differences between multigravid and primigravid sera were not statistically significant. Other expressed proteins were poorly recognized by sera, possibly because of problems with protein folding (data not shown).
![]() View larger version (15K): [in a new window] |
FIG. 6. PFD1140w seroreactivity. Recombinant PFD1140w is recognized by human sera from areas of malaria endemicity in a gender- and parity-dependent manner. (A) Coomassie-stained gel of affinity-purified cell-free expressed PFD1140w. Control, material purified from mock-translated reaction mixture. M, molecular mass markers with corresponding values (in kilodaltons). Low-molecular-mass material in both samples is FLAG peptide used for elution. (B) Reactivity of PFD1140w with sera from Muheza, Tanzania, where malaria transmission is intense. Multi, sera from multigravid women. Primi, sera from primigravid women. AU, arbitrary units. P, Mann-Whitney P value. N indicates the number of samples. The top of the box, bottom of the box, and line through the middle of the box correspond to the 75th, 25th, and 50th (median) percentiles, respectively. The whiskers indicate the 10th and 90th percentiles. (C) Reactivity of PFD1140w with sera from Kenya, where malaria transmission is intense. Male, sera from male donors. Other abbreviations and representations are as described for panel B.
|
|
|
|---|
Since var gene transcription is greatest during ring stage development (36), we speculated that other adhesion proteins or proteins related to the binding phenotype might have coordinated expression in ring stage parasites. We assumed that peripheral parasites were representative of placental parasites, because peripheral parasites of pregnant women mature into CSA-binding trophozoites (16, 17) and develop seroreactivity profiles similar to those of placental parasites (49). Consistent with this, we found a striking overlap in up-regulated genes from both peripheral and placental parasites (Table 4).
|
View this table: [in a new window] |
TABLE 4. Characteristics of genes with increased expression in pregnancy malaria parasites by microarray analysis
|
In contrast to the peripheral parasites analyzed here, the trophozoite stage samples fall into two distinct time classes at 24 h and 31 h of development. When the 31-h placental samples (PLCNT 038, PLCNT 222, and PLCNT 918) are compared to 31-h child-derived trophozoite samples (CH-TR 095 and CH-TR 852), a subset of the genes identified in the ring stage comparisons (PFD1140w, PFB0115w, PFI1785w, PFL0050c and PFL0030c/var2csa) are found to be expressed at two- to fourfold-higher levels in placental parasites (see Table S2 in the supplemental material). Comparison of the 24-h placental parasite samples (PLCNT 661 and PLCNT 166) with the 31-h trophozoites from children suggests a much higher level of differential expression in these genes (see Table S2 in the supplemental material), presumably due in part to the differences in cell cycle timing. This emphasizes the importance of determining the developmental stage of parasites in clinical samples.
var2csa is up-regulated in all parasite samples from women with pregnancy malaria. VAR2CSA is a semiconserved member of the PfEMP1 family (34, 60) that has been previously implicated as a mediator of adhesion to the placental receptor CSA. We found that var2csa was differentially expressed by both peripheral and placental binding parasites of pregnant women. In contrast, var2csa expression was reliably detected in only one child-derived sample (CH-PER 413), and here, only a few elements were hybridized and the signal was much less intense than those in maternal samples (Fig. 3B). The var2csa hybridization pattern of CH-PER 413 may have resulted from cross-hybridization with another expressed PfEMP1; however, this was not seen for other samples from children. Alternatively, the sequence of var2csa expressed by this parasite may diverge extensively from the sequence of var2csa expressed by parasites from pregnant women. Curiously, two elements recognized by the CH-PER 413 probe appear to be the most variant of those designed from conserved regions of this gene. This may indicate that a subset of var2csa variants is specifically associated with placental parasites.
Five genes are coexpressed with var2csa by parasites causing pregnancy malaria. We identified a small cohort of genes that mirror the var2csa expression profile in both peripheral and placental parasites from pregnant women. Genes included in this group predict proteins with transmembrane and/or signal sequences (Table 4). Three of the five differentially expressed genes identified here have putative export motifs (Table 4) that are consistent with transit to the erythrocyte (30, 44). PFD1140w has a PEXEL sequence (44), while PFL0050c and PFI1785w each have a VTS motif (30). Interestingly, PFI1785w belongs to a P. falciparum family composed of 16 uncharacterized hypothetical genes, most of which have predicted export sequences (PlasmoDB). PFB0115w and MAL13P1.320 have neither a PEXEL nor a VTS motif. However, this does not exclude trafficking of these proteins to the red blood cell by alternate export pathways, as has been suggested for skeleton binding protein 1 (sbp1 protein) and Maurer's cleft histidine-rich protein, which lack PEXEL/VTS motifs but nevertheless localize to the Maurer's clefts in the red blood cell cytoplasm.
Additional genes were differentially expressed by only ring stage or only mature-stage parasites from pregnant women and may play a role in the placental parasite phenotype as well. These genes include two members of the HISTa gene family (61), consisting of 42 paralogs in P. falciparum (P. falciparum gene database, Sanger Center [http://www.genedb.org/]) that encode proteins with putative PEXEL sequences (61) as well as PF10_0013, which has a PEXEL motif (44) and has been localized to the Maurer's cleft by proteomic analysis (68) (Table 4). Future studies will be required to determine whether these proteins are trafficked to the erythrocyte as well as how these expanded gene families affect the pathogenesis of P. falciparum malaria. A recent photolabeling study suggested that a 22-kDa protein on the IE surface may bind CSA (26). None of the genes identified here predict a protein of this size, although PF10_0013 (27.6 kDa) and MAL7P1.225 (29.9 kDa) predict slightly larger molecules.
Genes identified in the placental malaria cohort have been linked to adhesion phenotypes in two other microarray studies. Mok and coworkers found var2csa to be one of three var genes expressed at higher levels by rosetting parasites than by CD36-selected 3D7 parasites (45). This is curious because rosetting parasites are common in children, where var2csa transcription is atypical, but rarely observed in placental isolates, where var2csa transcription is generally detected (14, 56). Furthermore, the parasites selected to form rosettes failed to bind CSA (although they did bind to placental sections in a CSA-independent manner). Notably, PFB0115w was also differentially expressed by the rosetting parasites, suggesting that expression of var2csa and PFB0115w may be linked, as was seen in our study.
An earlier study used microarrays to compare FCR3 parasites selected to bind either CSA or CD36 (52). The microarrays included FCR3 var-specific probes to allow detection of PfEMP1 genes. CD36-selected cells differentially expressed a number of var genes, while only var2csa was differentially expressed by CSA-selected parasites. Many non-var genes were also found to have increased expression by FCR3 CSA-binding parasites, including PFB0115w, PFD1140w, and MAL13P1.470, which were among the most highly differentially expressed genes at both the ring and trophozoite stages (52). In contrast to the FCR3 study, we found only six genes with increased expression in all maternal parasite samples. The smaller cohort generated by our study might result because more samples were compared (8 maternal samples were compared to 11 samples from children) or because our studies used clinical samples that may better discriminate relevant genes. In the FCR3 study, two biological replicates were analyzed at the ring and trophozoite stages. The overlap in gene expression between parasites from women with pregnancy malaria and CSA-selected FCR3 parasites suggests that the genes identified here as belonging to the pregnancy malaria cohort merit further investigation. Our results suggest that only a few differentially expressed genes, including var2csa, distinguish placental parasites. However, due to sequence variation, we cannot exclude roles for highly polymorphic genes, like rifins, stevors, Pfmc-2TM, and other PfEMP1 genes, in the development of the placental parasite phenotype (9).
Seroreactivity of PFD1140w is gender and parity specific. VAR2CSA has been previously shown to have gender- and parity-specific recognition by immune serum that corresponds to the pattern of acquired immunity to pregnancy malaria (59, 67). PFD1140w showed a similar seroreactivity profile (Fig. 6). Whether antibodies against PFD1140w impair or block adhesion to CSA or have some other functional activity against placental parasites will be addressed in future studies. PFB0115w had higher reactivity with multigravid sera than with male sera, but these differences were not significant. PFB0115w should be studied in larger seroepidemiology surveys to assess whether this trend reflects a real difference in seroreactivity.
In conclusion, our results indicate that a small suite of genes is associated with the development of the placental parasite phenotype. Although the roles of the corresponding proteins in malaria pathogenesis or immunity remain unclear, we speculate that some of these proteins may have functions to interface with the pregnant host in the specialized milieu of the placenta, such as the putative role in which VAR2CSA adheres to CSA. Any proteins that localize to the surface of the IE will become important candidates for a pregnancy malaria vaccine, particularly in view of their highly conserved sequences. Defining the separate roles of these genes in the development of placental parasites could lead to a better understanding of mechanisms by which parasites acquire distinct binding properties and yield novel targets for intervention.
This work was supported by the U.S. National Institutes of Health (grant AI52059), the Bill and Melinda Gates Foundation (grant 29202), and the Grand Challenges in Global Health/Foundation for the NIH (grant 1364).
Published ahead of print on 13 August 2007. ![]()
Supplemental material for this article may be found at http://iai.asm.org/. ![]()
Present address: Merck & Co., Inc., Seattle, WA 98109. ![]()
Present address: University of Nebraska, Lincoln, NE. ![]()
|
|
|---|
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»